NICOX SA EUR1 (NASDAQ:NICXF) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday.
According to Zacks, “Nicox is an international commercial-stage company focused on the ophthalmic market. With a heritage of innovative R&D, business development and marketing expertise, they are building a diversified portfolio of ophthalmic products that can help people to enhance their sight. Nicox’s advanced pipeline features two pre-NDA candidates (Vesneo for glaucoma, partnered with Bausch + Lomb / Valeant and AC-170 for allergic conjunctivitis) as well as two pre-MAA candidates (AzaSite for bacterial conjunctivitis and BromSite for pain and inflammation after cataract surgery). The Group operates directly in six countries, including the United States. It has proprietary commercial operations in Europe’s five largest markets complemented by an expanding international network of distributors. Nicox is headquartered in France and has more than 120 staff worldwide. It is listed on Euronext Paris (Category B: Mid Caps) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. “
NICOX SA EUR1 (NASDAQ:NICXF) opened at 10.17 on Tuesday. NICOX SA EUR1 has a 52 week low of $1.69 and a 52 week high of $14.75. The stock’s market capitalization is $232.36 million. The stock’s 50 day moving average is $11.52 and its 200-day moving average is $10.96.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NICOX SA EUR1 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NICOX SA EUR1 and related companies with MarketBeat.com's FREE daily email newsletter.